Alligator Bioscience

The exercise period for warrants series TO 13 (“TO 13”) in Alligator
Bioscience AB (“Alligator Bioscience” or the “Company”) ended on 15 September 2025. The preliminary outcome indicates that a total of 8,903,880,000 TO 13 were exercised for subscription of 8,903,880 new ordinary shares for approximately SEK 27.8 million, corresponding to an exercise rate of approximately 90.6 percent. The final outcome will be published in a separate press release.

The exercise period for TO 13 took place during the period 1 – 15 September 2025. One thousand (1,000) TO 13 entitled the holder to subscribe for one (1) new ordinary share in the Company at a subscription price of SEK 3.12 per share. The preliminary outcome indicates that 8,903,880,000 TO 13, corresponding to approximately 90.6 percent of all TO 13, were exercised for subscription of a total of 8,903,880 ordinary shares. The preliminary outcome thus indicates that the Company will receive approximately SEK 27.8 million before issue costs.

The final outcome will be published in a separate press release which is expected to be announced on 17 September 2025.

Advisers
Vator Securities AB acts as Sole Global Coordinator and bookrunner in connection with the rights issue in which TO 13 were issued (the “Rights Issue”) and Van Lanschot Kempen N.V. acts as financial adviser to Alligator Bioscience in connection with the Rights Issue. Setterwalls Advokatbyrå AB is legal adviser to Alligator Bioscience in connection with the Rights Issue. Vator Securities AB acts as the issuing agent in connection with the Rights Issue.